AzTrials
AzTrials

KCNT1-Related EpilepsyK1TeNCT04924153

A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epilepsy

An observational study of KCNT1-Related Epilepsy, run by Biogen at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary objective of the study is to characterize seizures in participants with KCNT1-related epilepsy. The secondary objectives are to characterize head growth, symptom severity, neurocognitive and social functions, adaptive behavior, sleep, quality of life, caregiver burden, and mood in participants with… Read more about this study

Who is it for?
Ages 0 to 50 years
Conditions the study is for
KCNT1-Related Epilepsy
How many people
35 participants
Where
1 siteUnited States
Study dates
17 Aug 2021to 29 Aug 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 0 to 50 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: The study population include participants with KCNT1-related epilepsy.

Who may be able to join

  • Must have clinically and genetically confirmed diagnosis of KCNT1-related epilepsy provided by the investigator. For purposes of this study, mutations that are genetically confirmed to cause KCNT1-related epilepsy are defined to specifically exclude known benign variants (e.g., distal C terminus, splice site, etc.).
  • Willingness of the participant and/or the participant's legally authorized representative (LAR) to comply with scheduled visits and study procedures.

Who cannot join

  • Any condition that may interfere with the assessment of KCNT1-related epilepsy and that is clearly not related to this disease (in the judgment of the investigator).
  • History of human immunodeficiency virus infection.
  • History of central nervous system (CNS) tumors or malignancies, including CNS metastatic disease.
  • Current enrollment or past enrollment in an interventional clinical study in which an investigational gene therapy is/was administered.
  • Enrollment in an interventional clinical study in which an investigational small molecule, antibody or antisense oligonucleotide (ASO) treatment or approved small molecule, antibody or ASO therapy for investigational use is administered within 1 month (or 5 half-lives of study agent, whichever is longer) prior to the screening visit.
  • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Rochester

    Rochester, New York, 14642

Other trials in United States

About this study

Official title: A Non-Drug, Longitudinal, Prospective Natural History Study of Individuals With KCNT1-Related Epilepsy (K1Te)

The primary objective of the study is to characterize seizures in participants with KCNT1-related epilepsy. The secondary objectives are to characterize head growth, symptom severity, neurocognitive and social functions, adaptive behavior, sleep, quality of life, caregiver burden, and mood in participants with KCNT1-related epilepsy.

Being tested
No Intervention
Keywords
Epilepsy of Infancy with Migrating Focal Seizures (EIMFS), Early-Onset Epileptic Encephalopathy (EOEE), Sleep-Related Hypermotor Epilepsy (SHE), Autosomal Dominant Nocturnal Frontal Lobe Epilepsy (ADNFLE)
Medical subject headings
Autosomal Dominant Nocturnal Frontal Lobe Epilepsy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • No InterventionOther

    Administered as specified in the treatment arm.

Study groups in NCT04924153
Study groupRoleWhat they receive
EIMFS and EOEE (Up to 2 years)Participants who have been diagnosed with epilepsy of infancy with migrating focal seizures (EIMFS) and early-onset epileptic encephalopathy (EOEE) with duration of symptoms for up to 2 years will be enrolled.
Receives: Other: No Intervention
EIMFS and EOEE (More than 2 years)Participants who have been diagnosed with EIMFS and EOEE with duration of symptoms for more than 2 years will be enrolled.
Receives: Other: No Intervention
SHE (Up to 2 years)Participants who have been diagnosed with sleep-related hypermotor epilepsy (SHE) with duration of symptoms for up to 2 years will be enrolled.
Receives: Other: No Intervention
SHE (More than 2 years)Participants who have been diagnosed with SHE with duration of symptoms for more than 2 years will be enrolled.
Receives: Other: No Intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Seizures in Participants with KCNT1-Related Epilepsy, Assessed by Type

    Frequency and type of seizures as recorded daily by participants (or their caregivers/observers) in an electronic seizure diary.

    Measured: Up to Month 12

Secondary outcomes (24)
  1. Change from Baseline in Head Circumference

    Head circumference will be measured in participants under 18 years of age.

    Measured: Up to Month 12

  2. Clinical Global Impression-Severity (CGI-S) Scale Scores

    The CGI-S consists of a single 7-point rating score of illness severity. Raters select one response based on the following question: "Considering your total clinical experience with this particular population, how mentally ill is your participant at this time?" Scores are as follows: 1, normal, not ill at all; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill and 7, among the most severely ill participants. Higher scores indicate greater severity.

    Measured: Up to Month 12

  3. Clinical Global Impression-Change (CGI-C) Scale Scores

    The CGIC scale is a 7-point scale that requires the clinician to assess how much the participant's illness has changed relative to a baseline state at the beginning of the intervention, where 1, much better; 2, moderately better; 3, a little better; 4, the same; 5, a little worse; 6, moderately worse; 7, much worse. Higher rating will indicate worsening of the condition.

    Measured: Up to Month 12

  4. Participant-Specific Visual Analog Scale (VAS) for Most Concerning Symptoms Scores

    The participant-specific VAS for most concerning symptoms is a quality of life measurement that will be evaluated for the specified time periods. Participants report how they feel on a scale of 0 to 100, where 0 indicates being "poor" and 100 being "excellent." Up to 4 of the participant's most concerning symptoms will be assessed.

    Measured: Up to Month 12

  5. Vineland Adaptive Behavior Scales-Third Edition (Vineland-3) Composite Scores

    The Vineland-3 measures the personal and social skills of individuals from birth through adulthood. It includes 4 domains (communication, daily living skills, socialization, and motor skills) and 11 subdomains (3 each for communication, daily living skills, socialization and 2 for motor skills). Domain score ranges are as follows: 20 to 140, where 130-140, high; 115-129, moderately high; 86-114, adequate; 71-85, moderately low; 20-70, low. Composite scores are computed for each domain.

    Measured: Up to Month 12

  6. Vineland-3 Domain Scores

    The Vineland-3 measures the personal and social skills of individuals from birth through adulthood. It includes 4 domains (communication, daily living skills, socialization, and motor skills) and 11 subdomains (3 each for communication, daily living skills, socialization and 2 for motor skills). Domain score ranges are as follows: 20 to 140, where 130-140, high; 115-129, moderately high; 86-114, adequate; 71-85, moderately low; 20-70, low.

    Measured: Up to Month 12

  7. Vineland-3 Subdomain Scores

    The Vineland-3 measures the personal and social skills of individuals from birth through adulthood. It includes 4 domains (communication, daily living skills, socialization, and motor skills) and 11 subdomains (3 each for communication, daily living skills, socialization and 2 for motor skills). Subdomain score ranges from 1 to 24, where 21-24, high; 18-20, moderately high; 13-17, adequate; 10-12, moderately low and 1-9, low.

    Measured: Up to Month 12

  8. Assessment of Sleep Diary Features

    Sleep features, including total sleep time, time in bed and sleep latency. Sleep latency is defined as the amount of time taken to fall asleep after the lights have been turned off.

    Measured: Up to Month 12

  9. Number of Awakenings During Sleep

    Measured: Up to Month 12

  10. Brief Infant Sleep Questionnaire-Revised (BISQ-R) Total Scores

    BISQ-R is an age-based, norm-referenced scoring system that provides a comprehensive assessment of infant and toddler sleep patterns. It includes 3 subscales: infant sleep (IS), parent perception (PP) and parent behavior (PB). Total score ranging from 0-100 is calculated as an average of IS, PP and PB subscale scores. Higher scores denote better sleep quality, more positive perceptions of sleep quality, and parental habits that promote healthy sleep behaviors and independent infant sleep, respectively.

    Measured: Up to Month 12

  11. BISQ-R Subscale Scores

    BISQ-R is an age-based, norm-referenced scoring system that provides a comprehensive assessment of infant and toddler sleep patterns. It includes 3 subscales: IS, PP and PB. IS consists of 5 items related to sleep onset latency, number, and duration of night waking, longest stretch of sleep and total night sleep. PP consists of 3 items related to bedtime difficulty, overnight sleep, and overall child sleep problems. PB consisting of 11 items related to bedtime routine consistency, bedtime, parental behavior at time of sleep onset and night waking, sleep locations at time of sleep onset and following night waking that may impact sleep outcomes. Score ranging from 0-100 is derived for each sub-scale, with higher scores denoting better sleep quality, more positive perceptions of sleep quality, and parental habits that promote healthy sleep behaviors and independent infant sleep, respectively.

    Measured: Up to Month 12

  12. Children's Sleep Habits Questionnaire (CSHQ) Total Scores

    CSHQ is a parental report sleep screening instrument designed for preschool- and school-aged children. The scale yields both a total score and 8 subscales reflecting the following sleep domains: bedtime resistance, sleep onset delay, sleep duration, sleep anxiety, night wakings, parasomnias, sleep-disordered breathing, daytime sleepiness. Total score range between 33 and 99, with higher numbers representing more sleep problems.

    Measured: Up to Month 12

  13. CSHQ Subscale Scores

    CSHQ is a parental report sleep screening instrument designed for preschool- and school-aged children. The scale yields both a total score and 8 subscales reflecting the following sleep domains: bedtime resistance, sleep onset delay, sleep duration, sleep anxiety, night wakings, parasomnias, sleep-disordered breathing, daytime sleepiness. Score derived from each subscale range between 33 and 99, for bedtime resistance subscale, 6-18; for sleep onset/delay, 1-3; for sleep duration, 3-9; for sleep anxiety, 4-12; For night wakings, 3-9; for parasomnias, 7-21; for sleep-disordered breathing, 3-9; for daytime sleepiness, 8-24. For both total and subscale scores, higher values represent a worse outcome.

    Measured: Up to Month 12

  14. Pittsburgh Sleep Quality Index (PSQI) Total Scores

    The PSQI is a self-report questionnaire that assesses sleep quality over a 1-month time interval. It consists of 7 component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction, each of which can range from 0 to 3. The 7 components scores are then added to yield a global PSQI score in the range of 0 to 21. The higher score indicates worse sleep quality.

    Measured: Up to Month 12

  15. PSQI Subscale Scores

    The PSQI is a self-report questionnaire that assesses sleep quality over a 1-month time interval. It consists of 7 component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction, each of which can range from 0 to 3. The higher score indicates worse sleep quality.

    Measured: Up to Month 12

  16. Pediatric Quality of Life (PedsQL) Infant Scale Scores

    The PedsQL consists of 22 items comprising five dimensions: impact, cognitive functioning, sleep/rest, executive functioning, and mood/behavior that measures health related quality of life. The questionnaire asks how much of a problem each item has been during the past month. Each item is answered on a scale of 0 (never) to 4 (almost always) then the scores are transformed to a 0 to 100 scale, so that higher scores indicate better heath related quality of life.

    Measured: Up to Month 12

  17. PedsQL Core Scale Scores

    The PedsQL consists of 23 items in four generic score scales: physical functioning, emotional functioning, social functioning, and school functioning that measures health related quality of life. The questionnaire asks how much of a problem each item has been during the past month. Each item is answered on a scale of 0 (never) to 4 (almost always) then the scores are transformed to a 0 to 100 scale, so that higher scores indicate better heath related quality of life.

    Measured: Up to Month 12

  18. PedsQL Family Impact Module Scores

    The PedsQL consists of 36 items in eight dimensions: physical functioning, emotional functioning, social functioning, cognitive functioning, communication, worry, daily activities and family relationships that measures health related quality of life. The questionnaire asks how much of a problem each item has been during the past month. Each item is answered on a scale of 0 (never) to 4 (almost always) then the scores are transformed to a 0 to 100 scale, so that higher scores indicate better heath related quality of life.

    Measured: Up to Month 12

  19. Child Behavior Checklist for Ages 1.5 to 5-Language Development Survey (CBCL/1.5-5-LDS) Score

    LDS for ages of 18 months to 35 months is an important feature of the CBCL/1.5-5 which uses parent's reports to assess children's expressive vocabularies and word combinations, as well as risk factors for language delays. The LDS indicates whether a child's vocabulary and word combinations are delayed relative to norms for ages 18-35 months. The LDS can be completed for language-delayed older children for comparison with norms up to 35 months. Raw scores range from 0 to 310 words, more words is better, which are converted to a percentile ranking for gender/age based on normative data.

    Measured: Up to Month 12

  20. Child Behavior Checklist for Ages 6 to 18 (CBCL/6-18) Scores

    The CBCL/6-18 is aimed at assessing psychological adjustment and behavioral functioning of children, as rated by parents. This instrument provides a total score, an internalizing score and an externalizing score, together with 8 syndrome scale scores and 6 - Diagnostic and Statistical Manual of Mental Disorders (DSM)- oriented scale scores. It contains 113 items. Raw scores of the Total Problems Scale range from 0 to 226. Higher scores mean a worse outcome.

    Measured: Up to Month 12

  21. Adult Self-Report (ASR) Scores

    The ASR is a 126-item self-report questionnaire for adults assessing aspects of adaptive functioning and problems. The questionnaire provides scores for the following syndrome scales: anxious/depressed, withdrawn, somatic complaints, thought problems, attention problems, aggressive behavior, rule-breaking behavior, and intrusive behavior. The questionnaire provides scores for the following DSM-oriented scales: depressive problems, anxiety problems, somatic problems, avoidant personality problems, attention deficit/ hyperactivity problems (inattention and hyperactivity/impulsivity subscales), and antisocial personality problems. Additionally, the questionnaire asks about use of the following substances: tobacco, alcohol, and drugs. Items are rated on a 3-point scale: 0, not true; 1, somewhat or sometimes true; 2, very true or often true. Raw scores of the total problems scale range from 0 to 252. Higher scores mean a worse outcome.

    Measured: Up to Month 12

  22. Screen for Child Anxiety Related Emotional Disorders (SCARED)-Parent About Child Version Score

    The SCARED measures anxiety in children on a scale of 0 to 82, such that lower scores indicate low levels of anxiety, and high scores indicated high levels of anxiety.

    Measured: Up to Month 12

  23. Screen for Adult Anxiety Related Disorders (SCAARED)-Adult Version Scores

    The SCAARED measures anxiety in adults on a scale of 0 to 88 such that lower scores indicate lower levels of anxiety and high scores indicates higher levels of anxiety.

    Measured: Up to Month 12

  24. Questionnaire for Psychotic Experiences (QPE) Screening Version Scores

    The QPE is a questionnaire that is designed to quantify range of psychotic experiences, focusing on hallucinations and delusions. The 13-item screening version of the QPE that assesses the presence or absence of hallucinations and delusions will be used. Raw scores range from 0 to 26, with higher scores indicating more total and more recent symptoms.

    Measured: Up to Month 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jun 2021
  2. Study start17 Aug 2021
  3. Primary completion29 Aug 2023
  4. Study completion29 Aug 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
35 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04924153
Sponsor's protocol ID
992EP001
Acronym
K1Te
Status last verified
Feb 2024
First submitted
8 Jun 2021
Last updated
28 Feb 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Questions about this trial

What is this clinical trial studying?

An observational study of KCNT1-Related Epilepsy, run by Biogen at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Seizures in Participants with KCNT1-Related Epilepsy, Assessed by Type (time frame: Up to Month 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Feb 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in